March 2025 in “Molecules” This study explored the in vitro skin penetration of two compounds from Tectona grandis leaf extract used for standardization and found that compound 1 penetrates more efficiently than compound 2, especially with a propylene glycol enhancer.
March 2024 in “Journal of Evidence-Based Integrative Medicine” This study found that a hair tonic containing 1% teak leaf extract significantly increased hair growth and user satisfaction in men with androgenic alopecia after 24 weeks, without causing adverse effects, and was comparable to the standard treatment, minoxidil.
April 2022 in “Molecules” This study identified two potent 5α-reductase inhibitors from Tectona grandis leaves, and suggests that ethanol is a preferable solvent for extracting these compounds, which are potential ingredients for hair loss treatments.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
30 citations
,
December 2017 in “Medical Hypotheses” This review evaluates dihydrotestosterone's role in androgenic alopecia and proposes a model suggesting that chronic scalp tension and inflammation contribute to hair follicle miniaturization, identifying fibrosis, calcification, and tension as treatment targets.
12 citations
,
March 2017 in “Medicinal Chemistry Research” This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.
15 citations
,
October 2016 in “Steroids” This study developed and validated a label-free assay using LC-MS to screen for S5αR inhibitors, identifying Thai herbal extracts, Impatiens balsamina L. and Curcuma longa L., as promising sources.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
